Regorafenib

An orally administered multikinase inhibitor used to treat metastatic colorectal cancer, advanced gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma in selected patients previously treated with other systemic therapies. Regorafenib inhibits multiple kinases involved in tumor angiogenesis, oncogenic signaling, and the tumor microenvironment, including VEGFRs, TIE2, KIT, RET, RAF, and PDGFR. Its activity suppresses tumor vascularization and proliferation. Important adverse effects include hand-foot skin reaction, hypertension, diarrhea, fatigue, and potentially severe hepatotoxicity

CAS Number: 755037-03-7

Molecular Mass: 482.8 g/mol

Formula: C₂₁H₁₅ClF₄N₄O₃

Smiles: CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1

Synonymes:

Regorafenib, 755037-03-7, BAY 73-4506, Stivarga, Regorafenibum, BAY73-4506, BAY-73-4506, 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide, REGORAFENIB ANHYDROUS, 24T2A1DOYB, Bay-734506, 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide, BAY-734506 monohydrate, BAY 73-4506 monohydrate, CHEBI:68647, DTXSID60226441, BAY-73-4506 MONOHYDRATE, 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide, 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl}amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide, 4-(4-((4-chloro-3-(trifluoromethyl)phenyl)carbamoylamino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide, RefChem:57911, DTXCID60148932, L01XE21, 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)-3-fluorophenoxy)-N-methyl-, hydrate (1:1), MGN125FS9D, 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide, Regorafenib (BAY 73-4506), C21H15ClF4N4O3, MFCD16038047, 2-Pyridinecarboxamide,4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-, CHEMBL1946170, 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide, Stivarga (TN), 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluoro-phenoxy]-N-methyl-pyridine-2-carboxamide, Regorafenib [INN], Regorafenib [USAN:INN], UNII-24T2A1DOYB, Regorafenib (Standard), REGORAFENIB [MI], Regorafenib (USAN/INN), REGORAFENIB [VANDF], BAY73-4506 hydrochloride, REGORAFENIB [WHO-DD], MLS006010303, Regorafenib crystalline form I, SCHEMBL432230, Regorafenib,BAY 73-4506, GTPL5891, orb1307437, orb3141308, SCHEMBL29349808, SCHEMBL29351376, EX-A058, GLXC-90063, HMS3654K16, HMS3672E15, HMS5079O11, BDBM50363397, EBC-11382, HY-10331R, NSC763932, NSC800865, s1178, AKOS015951107, CCG-269571, CS-0170, DB08896, FR16116, NSC-763932, NSC-800865, SB16819, SDCCGSBI-0654355.P001, NCGC00263138-01, NCGC00263138-13, NCGC00263138-19, AC-25075, AC-31116, AS-16304, BP-44042, HY-10331, Regorafenib for FP system suitability CRS, SMR004701370, NS00040710, R0142, SW218097-2, cas:835621-07-3, Regorafenib hydrochloride, Regorafenib (BAY73-4506,Fluoro-Sorafenib), D10138, Regorafenib (BAY73-4506,Fluoro-Sorafenib)?, AB01565826_02, F361865, SR-01000941571, Q3891664, SR-01000941571-1, BRD-K16730910-001-02-4, BRD-K16730910-001-07-3, Z2235801830, 4-[4-({[4-Chloro-3-(trifluoromethy)phenyl]carbamoyl}amino)-3-fluorophenoxy]-1-methylpyridine-2-carboxamide, 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide

Bioactivity: Multikinase inhibitor; VEGFR-1/2/3, TIE2, PDGFR, FGFR, KIT, RET, and RAF kinase inhibitor; antiangiogenic antineoplastic agent

Solubility in Different Solvents

Solvent	Temperature [K]	Crystal form	Solubility [mg/mL]	Reference
1-Propanol	278.15	-	4.599	[149]
1-Propanol	283.15	-	5.02	[149]
1-Propanol	288.15	-	5.285	[149]
1-Propanol	293.15	-	5.867	[149]
1-Propanol	298.15	-	6.37	[149]
1-Propanol	303.15	-	7.686	[149]
1-Propanol	308.15	-	9.368	[149]
1-Propanol	313.15	-	10.89	[149]
Acetone	278.15	-	9.41	[149]
Acetone	283.15	-	11.53	[149]
Acetone	288.15	-	13.23	[149]
Acetone	293.15	-	16.27	[149]
Acetone	298.15	-	21.16	[149]
Acetone	303.15	-	24.34	[149]
Acetone	308.15	-	28.62	[149]
Acetone	313.15	-	33.72	[149]
Acetonitrile	278.15	-	1.32	[149]
Acetonitrile	283.15	-	1.512	[149]
Acetonitrile	288.15	-	1.557	[149]
Acetonitrile	293.15	-	1.868	[149]
Acetonitrile	298.15	-	2.266	[149]
Acetonitrile	303.15	-	2.713	[149]
Acetonitrile	308.15	-	3.433	[149]
Acetonitrile	313.15	-	4.402	[149]
Ethanol	278.15	-	5.395	[149]
Ethanol	283.15	-	5.663	[149]
Ethanol	288.15	-	6.148	[149]
Ethanol	293.15	-	7.164	[149]
Ethanol	298.15	-	7.506	[149]
Ethanol	303.15	-	9.028	[149]
Ethanol	308.15	-	10.27	[149]
Ethanol	313.15	-	11.78	[149]
Isopropanol	278.15	-	4.218	[149]
Isopropanol	283.15	-	4.336	[149]
Isopropanol	288.15	-	4.433	[149]
Isopropanol	293.15	-	4.857	[149]
Isopropanol	298.15	-	5.766	[149]
Isopropanol	303.15	-	6.811	[149]
Isopropanol	308.15	-	8.492	[149]
Isopropanol	313.15	-	9.927	[149]
Methanol	278.15	-	3.823	[149]
Methanol	283.15	-	4.234	[149]
Methanol	288.15	-	4.92	[149]
Methanol	293.15	-	5.032	[149]
Methanol	298.15	-	5.631	[149]
Methanol	303.15	-	6.847	[149]
Methanol	308.15	-	8.071	[149]
Methanol	313.15	-	9.28	[149]

Molecule 3D descriptors

Descriptor	Value
PMI1	2347.5815
PMI2	15259.3487
PMI3	15910.1395
NPR1	0.1476
NPR2	0.9591
RadiusOfGyration	5.8915
InertialShapeFactor	0.0004
Eccentricity	0.9891
Asphericity	0.6250
SpherocityIndex	0.1984
PBF	1.2695